Distinguished in Epidermolysis Bullosa with Pyloric Atresia

Christine Chiaverini

Nice, FR 
Distinguished in Epidermolysis Bullosa with Pyloric Atresia
Nice, FR 
OverviewLocationsClinical Research

Overview

Christine Chiaverini practices in Nice, France. Ms. Chiaverini is rated as a Distinguished expert by MediFind in the treatment of Epidermolysis Bullosa with Pyloric Atresia. Her top areas of expertise are Epidermolysis Bullosa, Dowling-Meara Epidermolysis Bullosa Simplex, Dominant Dystrophic Epidermolysis Bullosa, Keratosis Pilaris, and Gastrostomy.

Her clinical research consists of co-authoring 136 peer reviewed articles and participating in 2 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, she has co-authored 3 articles in the study of Epidermolysis Bullosa with Pyloric Atresia.

Gender
Female

Locations

Nice, France
Other Locations
CHU Lyon
Lyon, France
Strasbourg, France
Cambrai, France
Bordeaux, France
CHU Angers
Angers, France
St Louis Lariboisière University Hospital
Paris, France
Nantes, France
EA3181, 3, Boulevard Alexandre Fleming, Besancon, 25030, France

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

Double-blind, Randomised, Vehicle-controlled, Phase III, Efficacy and Safety Study With 24-month Open-label Follow-up of Oleogel-S10 in Patients With Inherited Epidermolysis Bullosa
Double-blind, Randomised, Vehicle-controlled, Phase III, Efficacy and Safety Study With 24-month Open-label Follow-up of Oleogel-S10 in Patients With Inherited Epidermolysis Bullosa
Enrollment Status: Completed
Publish Date: July 20, 2023
Intervention Type: Drug
Study Drug: Oleogel-S10
Study Phase: Phase 3
An International, Multicenter, Randomized, Double-Blind, Parallel-Group Phase 2 Study Evaluating the Safety and Efficacy of Diacerein 1% Ointment Topical Formulation in Subjects With Epidermolysis Bullosa Simplex
An International, Multicenter, Randomized, Double-Blind, Parallel-Group Phase 2 Study Evaluating the Safety and Efficacy of Diacerein 1% Ointment Topical Formulation in Subjects With Epidermolysis Bullosa Simplex
Enrollment Status: Terminated
Publish Date: November 05, 2019
Intervention Type: Drug
Study Phase: Phase 2
View 1 Less Clinical Trial

135 Total Publications

Correction: The PROPHECI trial: a phase II, double-blind, placebo-controlled, randomized clinical trial for the treatment of pseudoxanthoma elasticum with oral pyrophosphate.
Correction: The PROPHECI trial: a phase II, double-blind, placebo-controlled, randomized clinical trial for the treatment of pseudoxanthoma elasticum with oral pyrophosphate.
Journal: Trials
Published: April 02, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Ms. Chiaverini's expertise for a condition
ConditionClose
    View All 7 Distinguished Conditions
    View All 15 Advanced Conditions
    View All 64 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile